Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial

Medicine (Baltimore). 2017 Jul;96(27):e7371. doi: 10.1097/MD.0000000000007371.


Background: This study aimed to assess the efficacy and safety of atropine 0.5% eyedrops (ATE) for the treatment of children with low myopia (LM).

Methods: In this study, a total of 126 children with LM were randomly divided into an intervention group (administered 0.5% ATE) and a control group (administered a placebo), with 63 children in each group. The outcome measurements were changes in the spherical equivalent (SE), and axial length (AL), as well as adverse events (AEs).

Results: Compared with placebo, administration of 0.5% ATE led to less progression in LM, as measured by SE, and less increase in AL (P < .01). In addition, no serious AEs occurred in both the groups.

Conclusion: About 0.5% ATE was efficacious and safe for controlling myopia in children with LM.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Ophthalmic
  • Atropine / administration & dosage*
  • Atropine / adverse effects
  • Axial Length, Eye / drug effects
  • Child
  • Female
  • Humans
  • Male
  • Muscarinic Antagonists / administration & dosage*
  • Muscarinic Antagonists / adverse effects
  • Myopia / drug therapy*
  • Ophthalmic Solutions
  • Treatment Outcome


  • Muscarinic Antagonists
  • Ophthalmic Solutions
  • Atropine